Financial Performance - The company's operating revenue for the reporting period was ¥917,629,399.57, representing a year-on-year increase of 6.88%[3] - The net profit attributable to shareholders was ¥46,625,332.53, up 5.94% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,681,021.72, reflecting a growth of 2.07% year-on-year[5] - Basic earnings per share decreased by 20.55% to ¥0.51 due to an increase in share capital from public issuance[5] Assets and Equity - Total assets at the end of the reporting period reached ¥905,572,508.03, a 15.20% increase from the previous year[5] - Shareholders' equity attributable to the company increased by 60.49% to ¥458,569,610.02[5] - The company's net asset value per share rose by 20.37% to ¥5.06[5] - The increase in total assets and equity was primarily due to funds raised from public issuance and increased net profit during the reporting period[6] Challenges and Risks - The company faced challenges from the COVID-19 pandemic and industry conditions but focused on market expansion to ensure stable business growth[6] - The financial data presented is preliminary and has not been audited, cautioning investors to be aware of investment risks[7]
合肥高科(430718) - 2022 Q4 - 年度业绩